ImmunoPrecise Antibodies (IPA) to Release Quarterly Earnings on Friday

Posted by Editorial Team on Mar 26th, 2025

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Friday, March 28th. Analysts expect ImmunoPrecise Antibodies to post earnings of ($0.06) per share and revenue of $6.59 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

ImmunoPrecise Antibodies Price Performance

IPA stock opened at $0.44 on Wednesday. The company has a market capitalization of $13.67 million, a P/E ratio of -0.56 and a beta of 0.09. ImmunoPrecise Antibodies has a 52-week low of $0.27 and a 52-week high of $1.64. The company has a fifty day moving average price of $0.44 and a 200-day moving average price of $0.48. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of ImmunoPrecise Antibodies in a research report on Friday, March 14th.

Read Our Latest Stock Analysis on IPA

ImmunoPrecise Antibodies Company Profile

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.